BG-12 and its potential for the prevention of relapse in multiple sclerosis

References

• SadovnickADEbersGCEpidemiology of multiple sclerosis: a critical overviewCan J Neurol Sci19932017298467424
   PubMed Web of Science ®Google Scholar
• NoseworthyJHLucchinettiCRodriguezMWeinshenkerBGMultiple sclerosisN Engl J Med200034393895211006371
   PubMed Web of Science ®Google Scholar
• EvangelouNEsiriMMSmithSPalaceJMatthewsPMQuantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosisAnn Neurol20004739139510716264
   PubMed Web of Science ®Google Scholar
• WeinerHLThe challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?Ann Neurol20096523924819334069
   PubMed Web of Science ®Google Scholar
• Ben-NunAWekerleHCohenIRThe rapid isolation of clonable antigen specific T lymphocyte lines capable of mediating autoimmune encephalomyelitisEur J Immunol1981111951996165588
   PubMed Web of Science ®Google Scholar
• BartholomäusIKawakamiNOdoardiFEffector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesionsNature2009462949819829296
   PubMed Web of Science ®Google Scholar
• PrineasJWWrightRGMacrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosisLab Invest197838409421205724
   PubMed Web of Science ®Google Scholar
• OzawaKSuchanekGBreitschopfHPatterns of oligodendroglia pathology in multiple sclerosisBrain1994117131113227820568
   PubMed Web of Science ®Google Scholar
• RichardsRGSampsonFCBeardSMTappendenPA review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic modelsHealth Technol Assess20026173
   PubMedGoogle Scholar
• CottrellDAKremenchutzkyMRiceGPThe natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosisBrain199912262563910219776
   PubMed Web of Science ®Google Scholar
• KremenchutzkyMCottrellDRiceGThe natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluationBrain19991221941195010506095
   PubMed Web of Science ®Google Scholar
• ConfavreuxCVukusicSMoreauTAdeleinePRelapses and progression of disability in multiple sclerosisN Engl J Med20003431430143811078767
   PubMed Web of Science ®Google Scholar
• KremenchutzkyMRiceGPABaskervilleJWingerchukDMEbersGCThe natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the diseaseBrain200612958459416401620
   PubMed Web of Science ®Google Scholar
• ConfavreuxCVukusicSNatural history of multiple sclerosis: a unifying conceptBrain200612960661616415308
   PubMed Web of Science ®Google Scholar
• FeltsPABakerTASmithKJConduction in segmentally demyelinated mammalian central axonsJ Neurosci199717726772779295373
   PubMed Web of Science ®Google Scholar
• WaxmanSGDemyelinating diseases – new pathological insights, new therapeutic targetsN Engl J Med19983383233259445415
   PubMed Web of Science ®Google Scholar
• LovasGSzilágyiNMajtényiKPalkovitsMKomolySAxonal changes in chronic demyelinated cervical spinal cord plaquesBrain200012330831710648438
   PubMed Web of Science ®Google Scholar
• BjartmarCKiddGMörkSRudickRTrappBDNeurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patientsAnn Neurol20004889390111117546
   PubMed Web of Science ®Google Scholar
• PelletierDNelsonSJOhJMRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophyJ Neurol Neurosurg Psychiatr200374950952
   PubMed Web of Science ®Google Scholar
• RoccaMAIannucciGRovarisMComiGFilippiMOccult tissue damage in patients with primary progressive multiple sclerosis is independent of T2-visible lesions – a diffusion tensor MR studyJ Neurol200325045646012700912
   PubMed Web of Science ®Google Scholar
• ScalfariANeuhausADegenhardtAThe natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disabilityBrain20101331914192920534650
   PubMed Web of Science ®Google Scholar
• SormaniMPLiDBruzziPStubinskiBCombined MRI lesions and relapses as a perfect surrogate for disability in multiple sclerosisNeurology2011771684169021975200
   PubMed Web of Science ®Google Scholar
• AronsonKJQuality of life among persons with multiple sclerosis and their caregiversNeurology19974874809008497
   PubMed Web of Science ®Google Scholar
• InusahSSormaniMPCofieldSSAssessing changes in relapse rates in multiple sclerosisMult Scler2010161414142120810517
   PubMed Web of Science ®Google Scholar
• NicholasRStraubeSSchmidliHSchneiderSFriedeTTrends in annualized relapse rates in relapsing remitting multiple sclerosis and consequences for clinical trial designMult Scler2011171211121721586489
   PubMed Web of Science ®Google Scholar
• NaciHFleurenceRBirtJDuhigAEconomic burden of multiple sclerosis: a systematic review of the literaturePharmacoeconomics20102836337920402540
   PubMed Web of Science ®Google Scholar
• DaughertyKKButlerJSMattinglyMFactors leading patients to discontinue multiple sclerosis therapiesJ Am Pharm Assoc200545371375
   Google Scholar
• MillerDHWeinshenkerBGFilippiMBanwellBLCohenJAFreedmanMSDifferential diagnosis of suspected multiple sclerosis: a consensus approachMult Scler2008141157117418805839
   PubMed Web of Science ®Google Scholar
• CharilAYousryTARovarisMMRI and the diagnosis of multiple sclerosis: expanding the concept of ‘no better explanation’Lancet Neurol2006584185216987731
   PubMed Web of Science ®Google Scholar
• PolmanCHReingoldSCBanwellBDiagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaAnn Neurol20116929230221387374
   PubMed Web of Science ®Google Scholar
• SormaniMPBonzanoLRoccatagliataLCutterGRMancardiGLBruzziPMagnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approachAnn Neurol20096526827519334061
   PubMed Web of Science ®Google Scholar
• ChatawayJNicholasRToddSA novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosisMult Scler201117818820798135
   PubMed Web of Science ®Google Scholar
• GreenGToddJ‘Restricting choices and limiting independence’: social and economic impact of multiple sclerosis upon households by level of disabilityChronic Illn2008416017218796505
   PubMedGoogle Scholar
• TremlettHLLuscombeDKWilesCMPrescribing for multiple sclerosis patients in general practice: a case–control studyJ Clin Pharm Ther20012643744411722681
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study GroupInterferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trialNeurology1993436556618469318
   PubMed Web of Science ®Google Scholar
• JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)Ann Neurol1996392852948602746
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupNeurology199545126812767617181
   PubMed Web of Science ®Google Scholar
• PRISMS Study GroupRandomised double-blind placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosisLancet1998352149815049820297
   PubMed Web of Science ®Google Scholar
• PolmanCHO’ConnorPWHavrdovaEA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med200635489991016510744
   PubMed Web of Science ®Google Scholar
• RudickRAStuartWHCalabresiPANatalizumab plus interferon beta-1a for relapsing multiple sclerosisN Engl J Med200635491192316510745
   PubMed Web of Science ®Google Scholar
• ComiGDe StefanoNFreedmanMSComparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trialLancet Neurol201211334122146409
   PubMed Web of Science ®Google Scholar
• KinkelRPDontchevMKollmanCSkaramagasTTO’ConnorPWSimonJHAssociation between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological SurveillanceArch Neurol20126918319021987393
   PubMed Web of Science ®Google Scholar
• HohlfeldRBarkhofFPolmanCFuture clinical challenges in multiple sclerosis: relevance to sphingosine 1-phosphate receptor modulator therapyNeurology201176S28S3721339488
   PubMed Web of Science ®Google Scholar
• AltmeyerPJMatthesUPawlakFAntipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patientsJ Am Acad Dermatol1994309779818188891
   PubMed Web of Science ®Google Scholar
• AltmeyerPHartwigRMatthesUEfficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patientsHautarzt1996471901968647701
   PubMed Web of Science ®Google Scholar
• CarboniIDe FeliceCDe SimoniIFumaric acid esters in the treatment of psoriasis: an Italian experienceJ Dermatolog Treat200415232614754645
   PubMedGoogle Scholar
• LitjensNHNibberingPHBarroisAJBeneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokinesBr J Dermatol200314844445112653735
   PubMed Web of Science ®Google Scholar
• Fumapharm/Biogen Idec. BG12: BG00012, BG12/oral fumarate, FAG-201, second-generation fumarate derivativeDrugs R D2005622923015991882
   PubMedGoogle Scholar
• WerdenbergDJoshiRWolfframSMerkleHPLangguthPPresystemic metabolism and intestinal absorption of antipsoriatic fumaric acid estersBiopharm Drug Dispos20032425927312973823
   PubMed Web of Science ®Google Scholar
• Rostami-YazdiMClementBSchmidtTJSchinorDMrowietzUDetection of metabolites of fumaric acid esters in human urine: implications for their mode of actionJ Invest Dermatol200912923123418704112
   PubMed Web of Science ®Google Scholar
• LitjensNHRRademakerMRavensbergenBMonomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responsesEur J Immunol20043456557514768062
   PubMed Web of Science ®Google Scholar
• MrowietzUChristophersEAltmeyerPTreatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus ConferenceBr J Dermatol199914142442910584060
   PubMed Web of Science ®Google Scholar
• LiJJohnsonDCalkinsMWrightLSvendsenCJohnsonJStabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cellsToxicol Sci20058331332815525690
   PubMed Web of Science ®Google Scholar
• ChenX-LDoddGThomasSActivation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expressionAm J Physiol Heart Circ Physiol2006290H1862H187016339837
   PubMed Web of Science ®Google Scholar
• SatohTOkamatoSICuiJActivation of the Keap1/Nrf2 pathway for neuroprotection by electrophillic phase II inducersProc Natl Acad Sci U S A200610376877316407140
   PubMed Web of Science ®Google Scholar
• LeeJMShihAYMurphyTHJohnsonJANF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neuronsJ Biol Chem2003278379483795612842875
   PubMed Web of Science ®Google Scholar
• KraftADJohnsonDAJohnsonJANuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insultJ Neurosci2004241101111214762128
   PubMed Web of Science ®Google Scholar
• LeeJMCalkinsMJChanKKanYWJohnsonJAIdentification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide three times daily microarray analysisJ Biol Chem2003278120291203812556532
   PubMed Web of Science ®Google Scholar
• WierinckxABrevéJMercierDSchultzbergMDrukarchBVan DamA-MDetoxication enzyme inducers modify cytokine production in rat mixed glial cellsJ Neuroimmunol200516613214315993952
   PubMed Web of Science ®Google Scholar
• TreumerFZhuKGläserRMrowietzUDimethylfumarate is a potent inducer of apoptosis in human T cellsJ Invest Dermatol20031211383138814675187
   PubMed Web of Science ®Google Scholar
• de JongRBezemerACZomerdijkTPvan de Pouw-KraanTOttenhoffTHNibberingPHSelective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarateEur J Immunol199626206720748814248
   PubMed Web of Science ®Google Scholar
• KolenkoVBloomTRaymanPBukowskiRHsiEFinkeJInhibition of NF-kappa B activity in human T lymphocytes induces caspase-dependent apoptosis without detectable activation of caspase-1 and -3J Immunol199916359059810395645
   PubMed Web of Science ®Google Scholar
• VandermeerenMJanssensSBorgersMGeysenJDimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cellsBiochem Biophys Res Commun199723419239168952
   PubMed Web of Science ®Google Scholar
• MarsdenVSStrasserAControl of apoptosis in the immune system: Bcl-2, BH3-only proteins and moreAnnu Rev Immunol2003217110512414721
   PubMed Web of Science ®Google Scholar
• ZhuKMrowietzUInhibition of dendritic cell differentiation by fumaric acid estersJ Invest Dermatol200111620320811179994
   PubMed Web of Science ®Google Scholar
• RescignoMMartinoMSutherlandCLGoldMRRicciardi-CastagnoliPDendritic cell survival and maturation are regulated by different signaling pathwaysJ Exp Med1998188217521809841930
   PubMed Web of Science ®Google Scholar
• AsadullahKSchmidHFriedrichMInfluence of monomethyl-fumarate on monocytic cytokine formation – explanation for adverse and therapeutic effects in psoriasis?Arch Dermatol Res19972896236309444385
   PubMed Web of Science ®Google Scholar
• MurphyTHDe LongMJCoyleJTEnhanced NAD(P)H:quinone reductase activity prevents glutamate toxicity produced by oxidative stressJ Neurochem1991569909951704427
   PubMed Web of Science ®Google Scholar
• DuffySSoAMurphyTHActivation of endogenous antioxidant defenses in neuronal cells prevents free radical-mediated damageJ Neurochem19987169779648852
   PubMed Web of Science ®Google Scholar
• ShihAYJohnsonDAWongGCoordinate regulation of glutathi-one biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stressJ Neurosci2003233394340612716947
   PubMed Web of Science ®Google Scholar
• ShihAYLiPMurphyTHA small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivoJ Neurosci200525103211033516267240
   PubMed Web of Science ®Google Scholar
• ZhaoJMooreANRedellJBDashPKEnhancing expression of Nrf2-driven genes protects the blood brain barrier after brain injuryJ Neurosci200727102401024817881530
   PubMed Web of Science ®Google Scholar
• McMahonMItohKYamamotoMChanasSAThe Cap‘n’Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymesCancer Res2001613299330711309284
   PubMed Web of Science ®Google Scholar
• HubbsAFBenkovicSAMillerDBVacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2Am J Pathol20071702068207617525273
   PubMed Web of Science ®Google Scholar
• JohnsonDAAmirahmadiSWardCFabryZJohnsonJAThe absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitisToxicol Sci201011423724619910389
   PubMed Web of Science ®Google Scholar
• RachakondaGXiongYSekharKRStamerSLLieblerDCFreemanMLCovalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3Chem Res Toxicol20082170571018251510
   PubMed Web of Science ®Google Scholar
• LinkerRALeeD-HRyanSFumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathwayBrain201113467869221354971
   PubMed Web of Science ®Google Scholar
• OckenfelsHMSchultewolterTOckenfelsGFunkRGoosMThe antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine networkBr J Dermatol19981393903959767281
   PubMed Web of Science ®Google Scholar
• LoeweRValeroTKremlingSDimethylfumarate impairs melanoma growth and metastasisCancer Res200666118881189617178886
   PubMed Web of Science ®Google Scholar
• SchimrigkSBruneNHellwigKOral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot studyEur J Neurol20061360461016796584
   PubMed Web of Science ®Google Scholar
• PoserCMPatyDWScheinbergLNew diagnostic criteria for multiple sclerosis: guidelines for research protocolsAnn Neurol1983132272316847134
   PubMed Web of Science ®Google Scholar
• KapposLGoldRMillerDHEfficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLancet2520083721463147218970976
   PubMed Web of Science ®Google Scholar
• McDonaldWICompstonAEdanGRecommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosisAnn Neurol20015012112711456302
   PubMed Web of Science ®Google Scholar
• GoldRKapposLBar-OrAClinical efficacy of BG-12, an oral therapy, in relapsing-remitting multiple sclerosis: data from the phase 3 DEFINE trialMult Scler201117S34
   Google Scholar
• KapposLGoldRArnoldDLBG-12 effects on patient-reported outcomes in relapsing-remitting multiple sclerosis: results from the DEFINE studyMult Scler201217S488S489
   Google Scholar
• Biogen idec press releasePositive results from Phase 3 CONFIRM clinical trial show efficacy and safety of Oral BG-12 in multiple sclerosisDetailed CONFIRM Data Presented at 2012 American Academy of Neurology Annual MeetingRegulatory Applications Submitted to the FDA and EMAApril 24, 2012 Available from: http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1686377Accessed on September 1, 2012
   Google Scholar
• CohenJABarkhofFComiGTRANSFORMS Study GroupOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med201036240241520089954
   PubMed Web of Science ®Google Scholar
• SelmajKGoldRKapposLSafety and Tolerability of BG-12 in the Phase 3 DEFINE Trial in Patients with Relapsing-Remitting Multiple SclerosisPoster 994. Amsterdam, The Netherlands: 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis2011
   Google Scholar
• GoodinDSRederATEbersGCSurvival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trialNeurology2012781315132222496198
   PubMed Web of Science ®Google Scholar
• HartungH-PGonsetteRKönigNMitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trialLancet20023602018202512504397
   PubMed Web of Science ®Google Scholar
• RiceGPAIncorvaiaBMunariLInterferon in Relapsing-remitting Multiple SclerosisChichester, UKJohn Wiley & Sons, Ltd2006
   Google Scholar
• TremlettHLOgerJInterrupted therapy: stopping and switching of the beta-interferons prescribed for MSNeurology20036155155412939437
   PubMed Web of Science ®Google Scholar
• O’ConnorPFilippiMArnasonBBEYOND Study Group 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyLancet Neurol2009888989719729344
   PubMed Web of Science ®Google Scholar
• GoebJ-LEvenCNicolasGGohierBDubasFGarréJBPsychiatric side effects of interferon-beta in multiple sclerosisEur Psychiatry20062118619316386408
   PubMed Web of Science ®Google Scholar
• Meca-LallanaJEde Mingo-CasadoPAmorin-DíazMMartínez-NavarroMLBarreiroAFEffects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot studyClin Ther2010321061106620637960
   PubMed Web of Science ®Google Scholar
• CliffordDBDe LucaADeLucaANatalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 casesLancet Neurol2010943844620298967
   PubMed Web of Science ®Google Scholar
• LaroniAGiacomazziCGGrimaldiLUrinary JCV-DNA Testing during natalizumab treatment may increase accuracy of PML risk stratificationJ Neuroimmune Pharmacol2012766567222585413
   PubMed Web of Science ®Google Scholar
• BloomgrenGRichmanSHotermansCRisk of natalizumab-associated progressive multifocal leukoencephalopathyN Engl J Med20123661870188022591293
   PubMed Web of Science ®Google Scholar
• CalabresiPAGiovannoniGConfavreuxCThe incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINELNeurology2007691391140317761550
   PubMed Web of Science ®Google Scholar
• MarriottJJMiyasakiJMGronsethGO’ConnorPWEvidence report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyNeurology2010741463147020439849
   PubMed Web of Science ®Google Scholar
• GiovannoniGComiGCookSA placebo-controlled trial of oral cladribine for relapsing multiple sclerosisN Engl J Med201036241642620089960
   PubMed Web of Science ®Google Scholar
• EMEA assessment report. February 17, 2011. Procedure No. EMEA/H/C/2202 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002202/WC500104529.pdfAccessed on September 1, 2012
   Google Scholar
• O’ConnorPWolinskyJSConfavreuxCRandomized trial of oral teriflunomide for relapsing multiple sclerosisN Engl J Med20113651293130321991951
   PubMed Web of Science ®Google Scholar
• ComiGJefferyDKapposLPlacebo-controlled trial of oral laquinimod for multiple sclerosisN Engl J Med20123661000100922417253
   PubMed Web of Science ®Google Scholar
• KapposLRadueEWO’ConnorPFREEDOMS Study GroupA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med201036238740120089952
   PubMed Web of Science ®Google Scholar